DDAVP in childhood nocturnal enuresis

Acta Paediatr Scand. 1978 Nov;67(6):753-5. doi: 10.1111/j.1651-2227.1978.tb16255.x.

Abstract

A double-blind study of 18 children aged 6--12 years suffering from primary nocturnal enuresis without signs of underlying organic disease is reported. 20 microgram of DDAVP (desamino-D-arginine vasopressin, Minirin) was given intranasally at bedtime. The effect was prompt and satisfactory in 8 children and relatively good in another 8 children. No adverse effects were noted. DDAVP is advocated for temporary use in children with nocturnal enuresis needing immediate help.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Arginine Vasopressin / therapeutic use*
  • Child
  • Circadian Rhythm
  • Deamino Arginine Vasopressin / administration & dosage
  • Deamino Arginine Vasopressin / therapeutic use*
  • Double-Blind Method
  • Drug Evaluation
  • Enuresis / drug therapy*
  • Female
  • Humans
  • Placebos
  • Pregnancy

Substances

  • Placebos
  • Arginine Vasopressin
  • Deamino Arginine Vasopressin